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RENAL TRANSPLANTATION (RT) is an establishedmethod for the treatment of end-stage renal failure,
but there is an associated increased risk of cardiovascular
events. Long-term survival of renal transplant recipients
(RTRs) appears to be highly dependent on the occurrence
of cardiovascular complications. At present, cardiovascular
disease (CVD) is the leading cause of mortality in these
patients.1,2
Conventional CVD risk factors, such as hypertension,
hyperlipidemia, glucose intolerance, and obesity, are prob-
ably involved in the pathogenesis of atherosclerosis in this
setting. But traditional risk factors neither explain all of the
cardiovascular events nor completely account for why CVD
is the number one cause of death in RTRs.1,2
Increased plasma total homocysteine (tHcy) is consid-
ered to be a new and independent risk factor for CVD in
adults with normal or impaired renal function, including
stable RTRs; but little information exists about this condi-
tion in the pediatric age group.3–10
In the present study, we sought to: (1) analyze the
distribution of fasting tHcy levels to estimate the prevalence
of hyperhomocysteinemia in children adolescents bearing a
kidney allograft; (2) examine the relation between tHcy
levels and the vitamin cofactors (folic acid and vitamin B12),
renal function, immunosuppressive therapy, and other po-
tential determinants; and (3) assess the association between
hyperhomocysteinemia and conventional risk factors for
CVD.
SUBJECTS AND METHODS
A cross-sectional study was conducted in 25 pediatric RTRs (10
girls), 4 to 18 years old (mean age, 14.7  3.1 years). The eligibility
criteria were as follows: (1) RTRs younger than 19 years of age; (2)
minimum of 6 months since RT (3) stable plasma creatinine level
during the preceding 3 months; and (4) no clinical or analytical
evidence of liver disease.
The mean time after RT was 3.9  2.8 years (range, 8 months to
10 years); the mean serum creatinine and creatinine clearance
levels were 1.2  0.2 mg/dL and 64.5  8.9 mL/min/1.73m2,
respectively. No patient was on a dietary restriction or vitamin
supplementation. All kidney allografts were from cadaver donors.
The immunosuppression consisted of triple therapy with pred-
nisolone, cyclosporine, and mycophenolate mofetil (60%); pred-
nisolone, cyclosporine, and azathioprine (36%); or prednisolone
and cyclosporine (4%). One child received tacrolimus. Mean daily
prednisolone dosage was 0.14 mg/kg of body weight (range, 0.06 to
0.2) with 68% of patients on alternate-day regimens. The mean
daily cyclosporine dosage was 4.5 mg/kg of body weight (range, 0 to
6.4). Antihypertensive drugs were mainly angiotensin-converting
enzyme inhibitors and -blocking agents.
The study was approved by the Ethical Committee of Santo
Antonio Hospital. Written informed consent was obtained from
the parents of each participating child or adolescent.
Biochemical Determinations
After an overnight fast, venous blood samples were drawn into
EDTA-containing tubes. The sample intended for homocysteine
analysis was immediately put on ice, centrifuged within 30 minutes,
frozen, and stored at 20°C. Plasma tHcy levels were measured
using a fluorescence polarization immunoassay kit (IMx, Abbott
Laboratories, Axis Biochemical’s ASA, Oslo, Norway). The normal
range for tHcy was 5 to 15 mol/L. Vitamin B12, serum, and
erythrocyte folate concentrations were measured using commercial
chemiluminescence assay (ACS, Chiron Diagnosis). In our labora-
tory, normal levels of plasma vitamin B12, of plasma, and of
erythrocyte folate were 211–911 pg/mL, 2.6–20 ng/L, and 130–1102
ng/mL, respectively. Other biochemical parameters also were de-
termined on plasma using standard procedures, namely, creatinine,
urea, uric acid, total cholesterol, low-density lipoprotein (LDL)
and high-density lipoprotein (HDL) cholesterol, triglycerides, apo-
lipoproteins A and B, and lipoprotein(a). Creatinine clearance was
calculated using a 24-hour urine collection. All blood samples were
analyzed at the Clinical Chemistry Department of the Santo
Antonio Hospital.
Definition of Hyperhomocysteinemia
Levels of tHcy were compared with pediatric reference values for
tHcy, obtained from a healthy pediatric population near our
geographical area. Hyperhomocysteinemia was considered if tHcy
levels were greater than the 95th percentile of that population.11
Statistical Analysis
Results are reported as mean  SD and range (in parentheses).
Normality was tested by the Kolmogorov-Smirnov test. Because the
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data were normally distributed, Pearson’s correlation was used to
evaluate the relationship between continuous variables. Differ-
ences between means were analysed by Student t test or Mann-
Whitney U test. Frequencies of categorical variables were com-
pared using 2 test or Fisher exact test. All analyses were
performed using SPSS software for Windows, version 10.0, and a P
value of less than .05 was considered to indicate statistical signifi-
cance.
RESULTS
Mean fasting tHcy level was 14.9  4.3 mol/L (range, 5.2
to 33.5 mol/L), and 14 patients (56%) had tHcy levels 15
mol/L. Seventeen patients (68%) exhibited levels of tHcy
greater than the 95th percentile cut-off of published pedi-
atric reference values for tHcy11 (Fig 1).
No significant differences were observed between boys
and girls in the mean tHcy concentrations, namely, 15.5 
7.1 mol/L versus 14.0  2.7 mol/L (P  .556). A positive
significant linear correlation was observed between tHcy
and age (r  0.49; P  .05). There was no significant
correlation between tHcy and time post-RT, nor with the
length of hospitalization after RT.
None of the RTRs displayed a vitamin deficiency for any
of the evaluated vitamins. All patients had vitamin B12
levels within the normal range. Concerning plasma and
erythrocyte folate, 21 (84%) and 23 (92%) patients, respec-
tively, were within the normal range, and the remaining
patients showed plasma and erythrocyte folate levels
greater than the upper reference limit, namely, 3.3– 21 ng/L
in plasma, and 158–744 pg/mL in red blood cells. Levels of
tHcy were positively and significantly correlated with serum
creatinine (r  .45; P  .05), urea (r  .44; P  .05), and
uric acid (r  .47; P  .05), and inversely with creatinine
clearance (r  .46; P  .05).
None of the immunosuppressive (prednisolone, azathio-
prine, and mycophenolate mofetil) or antihypertensive
therapies (angiotensin-converting enzyme inhibitors and
-blocking agents) appeared to be significantly associated
with the occurrence of hyperhomocysteinemia.
The evaluated conventional risk factors for CVD were
widely prevalent in our pediatric sample: hypertension was
observed in 60% RTRs, obesity in 28%, hypercholesterol-
emia in 64%, and hypertriglyceridemia in 40%. One patient
had posttransplantation diabetes mellitus and only one
adolescent reported smoking.
None of the conventional risk factors was significantly
associated with hyperhomocysteinemia, and none of the
evaluated lipid parameters (total cholesterol, triglycerides,
LDL, HDL cholesterol, apolipoproteins A and B, and
lipoprotein(a)) was significantly correlated with tHcy levels.
Furthermore no correlation was found between body mass
index, blood pressure, and tHcy concentration.
DISCUSSION
Numerous studies have suggested that hyperhomocysteine-
mia represents an independent risk factor for atherosclero-
sis and atherothrombosis.4,12 These studies also have shown
that the relationship between tHcy concentration and vas-
cular disease risk appears to be continuous and graded:
each 5 mol/L increment in tHcy was associated with a 60%
to 80% higher risk of coronary artery disease, a 50% higher
risk of cerebrovascular disease, and a 6-fold higher risk of
peripheral vascular disease.12
Compared with the general population, renal patients,
including RTRs, display higher levels of tHcy.6 Our results
agree with other studies performed in adult and pediatric
RTRs that show a higher prevalence of hyperhomocysteine-
mia after RT.3–9 When compared with pediatric reference
ranges for tHcy,11 hyperhomocysteinemia was found in 68%
of our pediatric RTRs, or 56% if we considered the
threshold to be 15 mol/L.
Homocysteine is a sulfur-containing amino acid, which is
derived from the metabolism of methionine. Homocysteine
itself is metabolized by one of two pathways. Through a
vitamin B12-dependent reaction catalyzed by methionine
synthase, it may be remethylated to methionine, by 5-meth-
yltetrahydrofolate donating a methyl group. Alternatively,
homocysteine may enter the vitamin B6-dependent transul-
furation pathway, catalyzed by cystathionine -synthase,
where homocysteine is converted to cysteine.4,5,10,13 Thus,
folate, vitamin B12, and vitamin B6 status are important
biological determinants of tHcy levels.13 Increased Hcy
concentrations have been correlated with low serum levels
and low dietary intakes of vitamins B12, B6, and folate.
13 In
fact, subclinical deficiencies of these cofactors have been
shown to result in hyperhomocysteinemia.13 In our pediat-
ric RTRs, and in adult RTRs of our Unit,3 folic acid and
vitamin B12 levels were inversely correlated with tHcy
concentration, but hyperhomocysteinemia occurred despite
normal concentrations of folate and B12 vitamins. This
finding suggests that, besides the absence of vitamin defi-
ciencies, it is possible that higher vitamin concentrations are
required to normalize tHcy levels in RTRs.
By measuring tHcy in Spanish children aged from 2
months to 18 years, Vilaseca et al. reported that tHcy
concentrations increase with age.11 This positive correlation
was confirmed in our study. On the other hand, unlike adult
population (both general10,13 and RTRs3–6), where men
Fig 1. Distribution of tHcy (using the 95th percentile cut-off
value of the published11 pediatric reference values for tHcy).
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have higher tHcy levels than women, no significant differ-
ences were found between the genders in our pediatric
RTRs. Possible explanations for the higher concentrations
of tHcy in men may be the greater percentage of muscle
mass, and the beneficial hormonal effect exhibited by
women.4–6 It is possible that these differences are attenu-
ated in the pediatric population.
Like other studies that suggest that impaired renal func-
tion is strongly associated with increased Hcy levels,3–6 we
observed a positive and significant correlation between
tHcy and serum creatinine, urea, and uric acid levels and,
obviously, an inverse correlation with creatinine clearance.
Arnadottir et al. reported that cyclosporine might inter-
fere with homocysteine metabolism.6 Fonseca et al. found
lower tHcy levels in adult RTRs treated with mycopheno-
late mofetil (submitted for publication). In pediatric RTRs,
immunosuppressive (azathioprine, prednisolone, or my-
cofenolate mofetil) and antihypertensive therapies had no
significant effect on tHcy levels. We could not draw a
conclusion about the effect of cyclosporine on tHcy concen-
tration because almost all patients were taking this agent.
At the time of study, our pediatric RTRs showed a high
prevalence of traditional CVD risk factors, namely, hyper-
tension, dyslipidemia, and obesity. Like adult RTRs, hyper-
homocysteinemia was not significantly associated with the
presence of any of these conventional CVD risk factors.3
Furthermore, no significant correlation was observed be-
tween tHcy and plasma lipids, body mass index, or blood
pressure in this pediatric group.
In summary, hyperhomocysteinemia was widely prevalent
among our child and adolescent RTRs, which may contrib-
ute to an increased risk of CVD. Folic acid is known to be
an effective factor to reduce elevated tHcy levels. These
findings pose the question of whether an innocuous and
inexpensive therapy, such as folate supplementation, may
reduce the increased risk of CVD among pediatric RTRs.
Further prospective studies are needed to answer this
question.
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